Description

Depakin Chrono (sodium valproate) Coated Tablets with Prolonged Release 500 mg. №30

Ingredients:

Each coated tablet contains 500 mg of sodium valproate.

Dosage:

The usual starting dose for adults is 600 mg daily, divided into 2 doses. Dosage may be adjusted based on individual response.

Indications:

Depakin Chrono is indicated for the treatment of epilepsy and bipolar disorder. It helps control seizures and stabilize mood in patients with bipolar disorder.

Contraindications:

Do not use Depakin Chrono if you have liver disease, urea cycle disorders, or hypersensitivity to valproate or any components of the product.

Directions:

Swallow the tablets whole with a sufficient amount of water. Do not crush or chew the tablets. It is recommended to take the medication with food to reduce gastrointestinal side effects.

Scientific Evidence:

Depakin Chrono, containing sodium valproate, has been extensively studied for its efficacy in managing epilepsy and bipolar disorder. Research published in the Journal of Clinical Psychopharmacology demonstrated the effectiveness of sodium valproate in preventing manic episodes in patients with bipolar disorder. Additionally, a meta-analysis published in Epilepsia showed that sodium valproate is effective in reducing seizure frequency in patients with epilepsy.

Additional Information:

Depakin Chrono with prolonged release formulation offers the advantage of once-daily dosing, improving patient compliance and convenience. It is important to monitor liver function tests regularly during treatment with sodium valproate to detect any potential liver toxicity. Patients should be advised not to discontinue the medication abruptly, as it may lead to rebound seizures or mood swings.

Pharmacologically, sodium valproate works by increasing the levels of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits excessive neuronal activity. This mechanism helps in controlling seizures and stabilizing mood in patients with bipolar disorder.

Compared to other antiepileptic drugs, sodium valproate has shown comparable efficacy in seizure control with a favorable side effect profile. However, individual response to the medication may vary, and close monitoring by a healthcare provider is essential for optimal treatment outcomes.